免疫肿瘤学在头颈部癌治疗中不断演变的作用。
The evolving role of immuno-oncology for the treatment of head and neck cancer.
作者信息
Strome Arianna L, Zhang Xiaoyu, Strome Scott E
机构信息
School of Medicine University of Michigan Ann Arbor Michigan.
Department of Otorhinolaryngology-Head and Neck Surgery University of Maryland School of Medicine Baltimore Maryland.
出版信息
Laryngoscope Investig Otolaryngol. 2019 Jan 10;4(1):62-69. doi: 10.1002/lio2.235. eCollection 2019 Feb.
Monoclonal antibodies (mAbs) that target immune co-signaling pathways have the potential to enable immune mediated tumor eradication. While early adoption of these agents for the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) has produced some astounding clinical successes, the majority of patients fail to respond to therapy. The purpose of this review is to first provide a broad overview of the immuno-oncology (I-O) landscape and to then focus on the current status of mAb-based I-O (mAb:I-O) for the treatment of SCCHN, with particular attention to the development of strategies for improving treatment responses.
靶向免疫共信号通路的单克隆抗体（mAb）有潜力实现免疫介导的肿瘤根除。虽然这些药物早期用于治疗晚期头颈部鳞状细胞癌（SCCHN）已取得了一些惊人的临床成功，但大多数患者对治疗无反应。本综述的目的首先是对免疫肿瘤学（I-O）领域进行广泛概述，然后重点关注基于单克隆抗体的免疫肿瘤学（mAb:I-O）治疗SCCHN的现状，尤其关注改善治疗反应策略的发展。
Zotero 插件